Molecular mechanisms of HIV-1 protease resistance and resensitization towards lopinavir and saquinavir upon L76V mutation

被引：0
|
作者：
Bastys, T. [1 ]
Doncheva, N. T. [1 ]
Walter, H. [2 ]
Kaiser, R. [3 ]
Albrecht, M. [4 ,5 ]
Kalinina, O. V. [1 ]
机构：
[1] Max Planck Inst Informat, D-66123 Saarbrucken, Germany
[2] MIB, Berlin, Germany
[3] Univ Hosp Cologne, Inst Virol, Cologne, Germany
[4] Univ Med Greifswald, Greifswald, Germany
[5] Graz Univ Technol, A-8010 Graz, Austria
来源：
ANTIVIRAL THERAPY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
108
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [1] Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance
    de Mendoza, Carmen
    Garrido, Carolina
    Corral, Angelica
    Zahonero, Natalia
    Soriano, Vincent
    AIDS, 2008, 22 (02) : 311 - 313
  • [2] Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V
    Mueller, SM
    Daeumer, M
    Kaiser, R
    Walter, H
    Colonno, R
    Korn, K
    ANTIVIRAL THERAPY, 2004, 9 (04) : U44 - U45
  • [3] The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
    Frank Wiesmann
    Jan Vachta
    Robert Ehret
    Hauke Walter
    Rolf Kaiser
    Martin Stürmer
    André Tappe
    Martin Däumer
    Thomas Berg
    Gudrun Naeth
    Patrick Braun
    Heribert Knechten
    AIDS Research and Therapy, 8
  • [4] The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
    Wiesmann, Frank
    Vachta, Jan
    Ehret, Robert
    Walter, Hauke
    Kaiser, Rolf
    Stuermer, Martin
    Tappe, Andre
    Daeumer, Martin
    Berg, Thomas
    Naeth, Gudrun
    Braun, Patrick
    Knechten, Heribert
    AIDS RESEARCH AND THERAPY, 2011, 8
  • [5] Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease
    Young, Thomas P.
    Parkin, Neil T.
    Stawiski, Eric
    Pilot-Matias, Tami
    Trinh, Roger
    Kempf, Dale J.
    Norton, Michael
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) : 4903 - 4906
  • [6] Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes
    Charpentier, Charlotte
    Lambert-Niclot, Sidonie
    Alteri, Claudia
    Storto, Alexandre
    Flandre, Philippe
    Svicher, Valentina
    Perno, Federico
    Brun-Vezinet, Francoise
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Ceccherini-Silberstein, Francesca
    Descamps, Diane
    PLOS ONE, 2013, 8 (01):
  • [7] Clinically relevant resensitization of protease inhibitors (PIs) saquinavir and atazanavir (ATV) by L76V mutation in multidirug-resistant HIV-1-infected patients
    Braun, P.
    Walter, H.
    Hoffmann, D.
    Daeumer, M.
    Ehret, R.
    Korn, K.
    Thiele, B.
    Berg, T.
    Stuermer, M.
    Wiesmann, F.
    Kaiser, R.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S142 - S142
  • [8] Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease
    Wong-Sam, Andres
    Wang, Yuan-Fang
    Zhang, Ying
    Ghosh, Arun K.
    Harrison, Robert W.
    Weber, Irene T.
    ACS OMEGA, 2018, 3 (09): : 12132 - 12140
  • [9] Factors associated with the L76V protease mutation in HIV-1-infected patients with virological failure of lopinavir/ritonavir
    Baras, A.
    Champenois, K.
    Choisy, P.
    Yazdanpanah, Y.
    Bocket, L.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A114 - A114
  • [10] Clinically relevant resensitization of protease inhibitors (PIs) saquinavir and atazanavir (ATV) by L76V mutation in multidrug-resistant HTV-1-infected patients
    Braun, P.
    Walter, H.
    Hoffmann, D.
    Daeumer, M.
    Ehret, R.
    Korn, K.
    Thiele, B.
    Berg, T.
    Stuermer, M.
    Wiesmann, F.
    Kaiser, R.
    ANTIVIRAL THERAPY, 2007, 12 : S142 - S142
12345